Research has revealed regional disparities in outcomes for patients who are hospitalized with chemotherapy-related febrile neutropenia in the United States.
Immune checkpoint inhibitor retreatment in advanced melanoma is used in clinical practice, but there is a lack of evidence to support it, a study suggests.